Printed From:

Lantus® was evaluated for 52 weeks in insulin-naive patients with type 2 diabetes on OADs1

A1C decreased by

1.5%

in the Lantus® and detemir treatment groups and was comparable among groups after 52 weeks (7.1 % for Lantus® and 7.2% for detemir, respectively)

  • Overall, 52% of participants achieved A1C ≤7%

100% of Lantus® patients were dosed once a day throughout the study1

Safety results1

 

CV safety and A1C reductions
View the data on CV safety and A1C reductions

 

Reference

  1. Rosenstock J, Davies M, Home PD, et al. Diabetologia. 2008;51:408-416.